CC
KIN

Cannell Capital’s Kindred Biosciences, Inc. KIN Stock Holding History

Cannell Capital’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-196,318
Closed -$1.54M – 66
2017
Q3 		$1.54M Sell
196,318
-183,556
-48% -$1.38M 0.45% 37
2017
Q2 		$3.27M Buy
+379,874
New +$2.73M 0.93% 33

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
PVAM
Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

Cannell Capital's KIN Position: Q4 2017 in Review

Cannell Capital sold out of Kindred Biosciences, Inc. (KIN) in Q4 2017, closing a stake of 196,318 shares — an estimated $1.54M sold.

Cannell Capital first reported a position in KIN in Q2 2017 and held it in 2 quarters. The position peaked at $3.27M in Q2 2017. 61 funds tracked by Wall St. Rank hold KIN as of Q4 2017.

  • Cannell Capital reported no remaining Kindred Biosciences, Inc. position as of Q4 2017 after selling out during the quarter.
  • Cannell Capital sold 196,318 Kindred Biosciences, Inc. shares in Q4 2017, an estimated $1.54M.
  • Cannell Capital first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 2 quarters.
  • Cannell Capital's Kindred Biosciences, Inc. position peaked at $3.27M in Q2 2017.
  • 61 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2017.

Based on Cannell Capital's 13F filing for Q4 2017, filed 14 Feb 2018.